ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, the company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug Motegrity. U.S. annual sales for Prucalopride Tablets total approximately $168.0M, based on October 2024 moving annual total IQVIA data.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals initiated with an Outperform at Leerink
- ANI Pharmaceuticals Advances Amidst Regulatory and Market Challenges
- ANI Pharmaceuticals’ Record Growth and Strategic Acquisition
- ANI Pharmaceuticals reports Q3 adjusted EPS $1.34, consensus $1.09
- ANI Pharmaceuticals raises FY24 adj. EPS view to $4.90-$5.05 from $4.38-$4.82
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
